Timberlyne Therapeutics vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $180M Series A (Jan 2025). CM313 achieved 95% response rate in treatment-refractory ITP in NEJM-published data. Multi-indication 2026 pipeline. CD38 target with differentiated cytotoxicity.
About
Timberlyne Therapeutics launched in January 2025 with $180 million in Series A financing from Abingworth, Bain Capital Life Sciences, and Venrock, developing CM313 — an anti-CD38 monoclonal antibody with differentiated complement-dependent cytotoxicity properties. CM313 achieved a 95% response rate in treatment-refractory immune thrombocytopenia (ITP) in data published in the New England Journal of Medicine in 2025 — a 95% response rate in refractory patients is exceptional in autoimmune disease.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.